Form 4: Inozyme Pharma Director Lynne Marie Sullivan Acquires 28,000 Stock Options

Director Lynne Marie Sullivan acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024.

Summary

• On June 18, 2024, Lynne Marie Sullivan, a director of Inozyme Pharma, Inc., acquired 28,000 stock options.
• The exercise price of these options is $4.40.
• The options vest as to 100% of the shares on June 18, 2025, or immediately prior to the first annual meeting of stockholders occurring after the grant date.
• The options expire on June 17, 2034.
• Following the transaction, Sullivan directly owns 28,000 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates a director's increased stake in the company.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting changes in their beneficial ownership of company securities. It's a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in the pharmaceutical industry.
• The vesting schedule of one year is fairly standard.
• The exercise price is set at $4.40.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates